IL181819A - Use of benzo-fused compounds for the preparation of a medicament and methods making use of said compounds - Google Patents

Use of benzo-fused compounds for the preparation of a medicament and methods making use of said compounds

Info

Publication number
IL181819A
IL181819A IL181819A IL18181907A IL181819A IL 181819 A IL181819 A IL 181819A IL 181819 A IL181819 A IL 181819A IL 18181907 A IL18181907 A IL 18181907A IL 181819 A IL181819 A IL 181819A
Authority
IL
Israel
Prior art keywords
compounds
benzo
pharmaceuticals
preparation
compound
Prior art date
Application number
IL181819A
Other languages
English (en)
Hebrew (he)
Other versions
IL181819A0 (en
Original Assignee
St Vincents Inst Med Res
Florey Howard Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004905182A external-priority patent/AU2004905182A0/en
Application filed by St Vincents Inst Med Res, Florey Howard Inst filed Critical St Vincents Inst Med Res
Publication of IL181819A0 publication Critical patent/IL181819A0/en
Publication of IL181819A publication Critical patent/IL181819A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
IL181819A 2004-09-09 2007-03-08 Use of benzo-fused compounds for the preparation of a medicament and methods making use of said compounds IL181819A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004905182A AU2004905182A0 (en) 2004-09-09 Enzyme inhibitors and uses thereof
PCT/AU2005/001380 WO2006026832A1 (en) 2004-09-09 2005-09-09 Enzyme inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
IL181819A0 IL181819A0 (en) 2007-07-04
IL181819A true IL181819A (en) 2013-07-31

Family

ID=36036029

Family Applications (1)

Application Number Title Priority Date Filing Date
IL181819A IL181819A (en) 2004-09-09 2007-03-08 Use of benzo-fused compounds for the preparation of a medicament and methods making use of said compounds

Country Status (13)

Country Link
US (1) US20080194636A1 (cg-RX-API-DMAC7.html)
EP (1) EP1789079B1 (cg-RX-API-DMAC7.html)
JP (1) JP5031567B2 (cg-RX-API-DMAC7.html)
KR (1) KR20070100878A (cg-RX-API-DMAC7.html)
CN (1) CN101039690A (cg-RX-API-DMAC7.html)
CA (1) CA2579768A1 (cg-RX-API-DMAC7.html)
DK (1) DK1789079T3 (cg-RX-API-DMAC7.html)
ES (1) ES2403340T3 (cg-RX-API-DMAC7.html)
IL (1) IL181819A (cg-RX-API-DMAC7.html)
NZ (1) NZ553688A (cg-RX-API-DMAC7.html)
SG (1) SG155901A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006026832A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200702041B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263775B2 (en) 2007-11-19 2012-09-11 Howard Florey Institute Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof
CN101284820B (zh) * 2008-04-25 2011-05-04 南昌大学 一种氨肽酶抑制剂及合成方法
CN103848805A (zh) * 2012-12-06 2014-06-11 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103896900A (zh) * 2012-12-25 2014-07-02 韩冰 一类具有神经保护作用的化合物及其制备方法和用途
PL3150581T3 (pl) 2014-05-28 2020-07-13 Astellas Pharma Inc. Pochodne pirydyny
AR102849A1 (es) 2015-03-09 2017-03-29 Astellas Pharma Inc Compuesto de piridina bicíclica
WO2017015720A1 (en) 2015-07-30 2017-02-02 Monash University Fibrotic treatment
WO2023099589A1 (en) 2021-12-01 2023-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Irap inhibitors for use in the treatment of inflammatory diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284868A (en) * 1991-10-09 1994-02-08 Eli Lilly And Company Pharmaceutical compounds
US5281619A (en) 1992-09-25 1994-01-25 Eli Lilly And Company Therapy for diabetic complications
EP1004584A3 (en) 1992-11-18 2000-07-05 Eli Lilly And Company Limited Pyranoquinoline derivatives as inhibitors of cell proliferation
US6680332B1 (en) * 1999-06-04 2004-01-20 Euro-Celtique S.A. Substituted 5-oxo-5,6,7,8-tetrahydro-4H-1-benzopyrans and benzothiopyrans and the use thereof as potentiators of AMPA
EP1392683B1 (en) * 2001-05-16 2009-12-02 Cytovia, Inc. Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and their use as anticancer agents
US20050020519A1 (en) * 2001-08-02 2005-01-27 Albiston Anthony L. Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at4) receptor activity
US20030114418A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor
PL372488A1 (en) * 2002-02-13 2005-07-25 F.Hoffmann-La Roche Ag Novel pyridine- and quinoline-derivatives
US8263775B2 (en) * 2007-11-19 2012-09-11 Howard Florey Institute Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof

Also Published As

Publication number Publication date
IL181819A0 (en) 2007-07-04
EP1789079B1 (en) 2012-11-07
JP5031567B2 (ja) 2012-09-19
US20080194636A1 (en) 2008-08-14
EP1789079A4 (en) 2010-09-01
SG155901A1 (en) 2009-10-29
JP2008512395A (ja) 2008-04-24
EP1789079A1 (en) 2007-05-30
NZ553688A (en) 2011-05-27
CN101039690A (zh) 2007-09-19
ZA200702041B (en) 2008-09-25
CA2579768A1 (en) 2006-03-16
WO2006026832A1 (en) 2006-03-16
DK1789079T3 (da) 2013-03-11
ES2403340T3 (es) 2013-05-17
KR20070100878A (ko) 2007-10-12

Similar Documents

Publication Publication Date Title
TWI350168B (en) Amido compounds and their use as pharmaceuticals
IL188732A (en) Use of ibuprofen and famotidine in the preparation of medicaments
BRPI0614205A2 (pt) composto, composição farmacêutica, e, uso de composto
EP1773780A4 (en) AMIDO COMPOUNDS AND USES THEREOF AS PHARMACEUTICAL PRODUCTS
IL181174A0 (en) Amido compounds and their use as pharmaceuticals
EP1758882A4 (en) AMID COMPOUNDS AND THEIR USE AS MEDICAMENTS
IL179519A0 (en) Amido compounds and their use as pharmaceuticals
EP1773773A4 (en) AMID COMPOUNDS AND THEIR USE AS MEDICAMENTS
BRPI0714539A2 (pt) "formas farmacêuticas"
DK3424932T3 (da) Bronophthalider til terapeutisk anvendelse
DK2079485T3 (da) Phenylpropionamidforbindelser og anvendelsen deraf
CR10725A (es) Compuestos de pirazolina y su uso y composiones farmaceuticas
BRPI0813587A2 (pt) Composto, uso do mesmo, e, composição farmacêutica
BRPI0720323A2 (pt) composto, método de tratamento, composição farmacêutica e uso do composto
DK2033629T3 (da) Fast farmaceutisk sammensætning omfattende valsartan
BRPI0716425A2 (pt) Nucleosídeos, fármacos contendo estes e uso destes
PT1763520E (pt) Utilização de benzopiranonas trissubstituídas
BRPI0611748A2 (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
BRPI0615630A2 (pt) composição farmacêutica, e, uso de sertindol
BRPI0617943A2 (pt) composto farmacêutico e uso de um composto farmacêutico
ITMI20041447A1 (it) Composizione farmaceutica comprendente gabapentina
ITMI20051957A1 (it) Composti e relativo uso per il controllo di fitoparogeni
ITMI20040943A1 (it) Composizione farmaceutica cicatrizzante
ITMI20052464A1 (it) Procedimento per la preparazi9one di norelgestromin norelgestromina
SE0402638D0 (sv) Pharmaceutical use

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees